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Summary  Ventricular  assist  devices  (VADs)  have  become  an  established  therapeutic  option
for patients  with  end-stage  heart  failure.  The  appearance  of  heart  failure  in  VAD  patients  seems
unexpected.  Nevertheless,  this  phenomenon  is  not  rare.  We  report  six  cases  of  VAD  patients
with clinical  presentation  of  heart  failure  at  different  times  after  implantation  and  describe  the
mechanisms  involved.  The  aetiology  of  this  heart  failure,  like  its  clinical  presentation,  varies
and has  yet  to  be  identiﬁed.
© 2012  Published  by  Elsevier  Masson  SAS.MOTS  CLÉS
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Résumé  L’assistance  circulatoire  mécanique  (ACM)  de  longue  durée  est  devenue  un  traite-
ment de  l’insufﬁsance  cardiaque  terminale.  Elle  améliore  la  qualité  de  vie  et  la  survie  de
ces patients.  L’apparition  d’une  insufﬁsance  cardiaque  chez  les  patients  assistés  est  inatten-
due. Pourtant  ce  phénomène  n’est  pas  rare.  Il  est  important  d’identiﬁer  cette  insufﬁsance
cardiaque  et  de  préciser  les  mécanismes  aﬁn  de  proposer  un  traitement  adapté.  Les  objectifs
Abbreviations: BiVAD, biventricular assist device; CI, cardiac index; CVP, central venous pressure; HF, heart failure; INTERMACS, Inter-
gency Registry for Mechanically Assisted Circulatory Support; LV, left ventricular; LVAD, left ventricular assist device; NYHA, New York
eart Association; PAC, pulmonary artery catheterization; PCWP, pulmonary capillary wedge pressure; rpm, revolutions per minute; RV,
ight ventricular; RVAD, right ventricular assist device; RVF, right ventricular failure; TAH, total artiﬁcial heart; VAD, ventricular assist
evice.
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de  cette  revue  sont  de  décrire  les  différentes  étiologies  de  l’insufﬁsance  cardiaque  sous  ACM,
leurs présentations  cliniques  et  leurs  prises  en  charge.  Cette  revue  sera  illustrée  par  six  cas
d’insufﬁsance  cardiaque  survenue  à  des  moments  différents  de  l’implantation  de  l’ACM.
© 2012  Publié  par  Elsevier  Masson  SAS.
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Ventricular  assist  devices  (VADs)  have  become  an  established
therapeutic  option  for  patients  with  end-stage  heart  failure
(HF)  [1,2]. VADs  support  either  the  left  ventricle  (LVAD)  or
both  ventricles  (BiVAD)  [3].  The  output  of  these  devices  is
able  to  provide  a  systemic  ﬂow  close  to  normal  values  at
rest.  Owing  to  this  capability,  the  occurrence  of  HF  during
mechanical  support  is  not  expected.
HF  is  deﬁned  as  a  clinical  syndrome  characterized  by  spe-
ciﬁc  symptoms  (dyspnoea  and  fatigue)  in  the  medical  history
and  by  signs  of  ﬂuid  retention  (pulmonary  congestion  and
peripheral  oedema)  on  physical  examination  [4,5]. The  usual
laboratory  tests  can  help  to  conﬁrm  the  diagnosis  but  their
use  is  limited  in  VAD  patients  [6].  The  assessment  of  ﬁlling
pressure  in  echocardiography  remains  difﬁcult  because  the
validity  of  standard  variables  is  uncertain  in  severe  dilated
cardiomyopathy  [7]  and  difﬁcult  to  prove  in  LVAD  patients
when  an  inﬂow  cannula  is  implanted  in  the  left  ventricle.
The  use  of  pulmonary  artery  catheterization  (PAC)  can  be
dangerous  in  BiVAD  patients  and  is  contraindicated  in  contin-
uous  BiVAD  and  total  artiﬁcial  heart  (TAH)  patients  because
it  is  potentially  fatal  [8,9]. We  considered  acute  episodes
of  left  HF,  right  HF  and  global  HF.  The  diagnosis  was  made
when  dyspnoea  with  rales  and  pulmonary  congestion  was
present  on  X-ray  examination  (with  no  indication  of  infec-
tion  or  acute  lung  injury)  and/or  peripheral  oedema.  The
diagnosis  was  consolidated  with  increased  central  venous
pressure  (CVP)  and/or  pulmonary  capillary  wedge  pressure
(PCWP)  when  right  catheterization  or  CVP  measurements
were  possible  [10].
If  HF  occurs,  its  potential  impact  on  patient  outcome
can  be  very  signiﬁcant,  in  terms  of  prolonged  mechanical
ventilation  plus  its  consequences,  as  well  as  increased  risk
of  infection  multiorgan  failure,  delayed  rehabilitation  and
longer  duration  of  hospitalization.  There  are  no  data  in  the
literature  on  HF  in  patients  with  VADs.
We  report  six  cases  in  which  VAD  patients  presented  HF
at  different  times  after  implantation  and  try  to  describe  the
different  causes  of  the  clinical  presentation.
Clinical summaries
HF within the ﬁrst week post-VAD insertionPatient  1:  HeartWare  LVAD  —  multifactorial  HF
A  66-year-old  man  with  ischaemic  cardiomyopathy  and  low
ejection  fraction  had  presented  New  York  Heart  Association
(NYHA)  stage  IV  symptoms  since  2009  (Tables  1  and  2).  He
o
2
a
oad  chronic  renal  insufﬁciency  (creatinine  1.8  mg/dL).  PAC
n  June  2009  showed  a  cardiac  index  (CI)  of  1.6  L/min/m2.
n  November  2010,  the  patient  received  a  HeartWare  LVAD
s  destination  therapy  because  he  developed  new  cardio-
enic  shock  with  progressive  decline  on  inotropic  drugs
Interagency  Registry  for  Mechanically  Assisted  Circulatory
upport  [INTERMACS]  2).  INTERMACS  levels  are  clinical
tages  that  were  developed  and  implemented  into  the  ﬁrst
ear  of  data  collection  for  the  INTERMACS  [11]; they  are
elpful  for  evaluating  the  prognosis  of  patients  after  VAD
mplantation.  Each  level  deﬁnes  clinical  status:  level  1,  crit-
cal  cardiogenic  shock;  2,  progressive  decline;  3,  stable  but
notrope  dependent;  4,  recurrent  advanced  HF;  5,  exer-
ion  tolerance;  6,  exertion  limited;  and  7,  advanced  NYHA
II  [11].
The PAC  measurements  on  the  day  of  implantation
hile  the  patient  received  inotropic  drugs  were:  CI,
.26  L/min/m2;  CVP,  4  mmHg;  and  PCWP,  12  mmHg.  On
he  day  of  surgery  the  patient  received  5470  L  of  ﬂu-
ds  and  diuresis  was  3350  L.  After  LVAD  implantation,  the
atient  was  immediately  extubated  but  ventilation  perfor-
ance  was  impaired.  The  estimated  ﬂow  of  the  LVAD  was
.9  L/min  at  2900  revolutions  per  minute  (rpm).  The  CVP
as  18  mmHg  and  the  PCWP  was  27  mmHg.  X-ray  exami-
ation  indicated  alveolar-interstitial  oedema.  The  patient
as  treated  by  non-invasive  ventilation  and  intravenous
iuretics.  The  status  of  the  patient  deteriorated  further
nd  he  needed  mechanical  ventilation.  The  patient  was
nally  extubated  after  15  days.  He  was  rehabilitated  suc-
essfully  and  discharged  after  a total  of  6  weeks  of  hospital
upport.
The  symptoms  could  be  explained  by  impaired  renal  func-
ion,  relative  volume  overload  and  the  long  period  of  low
ardiac  output  syndrome.
atient  2:  Biventricular  Thoratec  VAD  —
ultifactorial  HF
 41-year-old  man  presented  with  a  6-month  history  of
ilated  cardiomyopathy  and  a  thrombus  in  the  left  ventricle.
he  thrombus  was  evacuated  by  ventriculotomy  at  the  end
f  September  2010  but  weaning  from  the  bypass  was  impos-
ible.  The  patient  received  venoarterial  extracorporeal
embrane  oxygenation.  Haemodynamic  status  and  echocar-
iographic  ﬁndings  precluded  weaning.  The  patient  received
 biventricular  Thoratec  paracorporeal  VAD  (BiVAD)  because
f  biventricular  dysfunction  at  the  beginning  of  November
010;  his  respiratory  status  improved  and  he  was  extubated
fter  3  days.  Nevertheless,  he  needed  oxygen  and  devel-
ped  peripheral  oedema.  The  right  ventricular  assist  device
46  N.  Aissaoui  et  al.
Table  1  Summary  of  patients.
Patient  Age
(years)
INTERMACS  Type  of  VAD  Timing  of
appearance
Clinical
presentation
Aetiology  of  HF  Outcome
1 66  2  LVAD  HeartWare  1  week  Pulmonary
oedema
Multifactorial  Discharged
2  41  1  BiVAD  Thoratec  1  week  Pulmonary  and
peripheral
oedema
Multifactorial  Discharged
3  24  3  LVAD  2  weeks  Pulmonary
oedema
RVF Discharged
4  41  1  BiVAD  HeartWare  1  month  Pulmonary
oedema
Pulmonary
overﬂow  of  RVAD
and  tamponade
Discharged
5  58  2  TAH  2  months  Pulmonary  and
peripheral
oedema
Multifactorial  Discharged
6  72  —  LVAD  VentrAssist  1  year  Pulmonary  and
peripheral
oedema
Device
malfunction
Death
BiVAD: biventricular assist device; HF: heart failure; LVAD: left ventricular assist device; RVAD: right ventricular assist device; RVF: right
ventricular failure; TAH: total artiﬁcial heart; VAD: ventricular assist device.
Table  2  Biological  variables.
Patient Creatinine BUN Plasma  protein  ASAT  ALAT  PT
(mg/dL) (mg/dL) (g/dL)  (IU/L)  (IU/L)  (%)
1  Before  1.8  62  6.1  27  31  83
At  the  time  of  HF  1.9  74  6.0  87  15  49
2 Before 2.1  205  4.5  17  23  42
At  the  time  of  HF 1.8  180  4.5  14  2  31
3  Before  0.81  13  6.2  28  39  70
At  the  time  of  HF  0.7  30  6.2  73  64  57
4 Before 1.3  79 6.6  5830  2910  29
At  the  time  of  HF 0.64  32 5.9  115 92  79
5  Before  2.1  157  5.6  293  220  89
At  the  time  of  HF  1.3  100  6.1  36  22  29
6  Before  0.86  30  7.4  33  10  37
At  the  time  of  HF  3.1  116  6.7  751  746  8
ASAT: aspartate aminotransferase; ALAT: alanine aminotransferase; BUN: blood urea nitrogen; HF: heart failure; PT: prothrombin time.
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wRVAD)  ﬂow  was  4.8  L/min  and  the  LVAD  ﬂow  was  6.6  L/min.
ystolic  arterial  pressures  were  about  90  mmHg  and  CVP
as  20  mmHg.  Renal  function  was  impaired  (creatinine
.1  mg/dL)  and  plasma  protein  was  decreased  (4.5  g/dL).
chocardiography  eliminated  tamponade  and  radiography
howed  alveolar-interstitial  oedema.  Oedema  decreased
fter  4  days  of  intravenous  high-dose  diuretics.  Thirty  days
fter  the  operation,  the  patient  was  discharged  with  BiVAD
upport.The  clinical  presentation  could  be  explained  by  the  long
eriod  of  low  cardiac  output  syndrome,  impaired  renal  func-
ion,  poor  nutritional  status  and  vasoplegia  induced  by  the
wo  cardiac  surgical  interventions.
M
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iF within the ﬁrst month post-VAD insertion
atient  3:  HeartWare  LVAD  —  right  ventricular  (RV)
ailure
 24-year-old  man  was  diagnosed  with  dilated  cardiomyopa-
hy  and  low  ejection  fraction  (<  25%)  present  for  6 weeks
nd  of  unknown  origin.  He  was  hospitalized  at  the  begin-
ing  of  January  2011  for  a  ﬁrst  episode  of  cardiogenic  shock
ith  impossibility  of  weaning  from  inotropic  drugs  (INTER-
ACS  3).  PAC  (with  inotropic  drugs)  before  the  implantation
evealed:  CI,  2.68  L/min/m2;  PCWP,  13  mmHg;  and  CVP,
 mmHg.  The  patient  was  a  drug  addict  and  we  decided  to
mplant  a  HeartWare  LVAD  as  a  bridge  to  a  decision.
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At  day  8,  the  patient  presented  respiratory  insufﬁciency;
CVP  was  16  mmHg  and  the  ﬂow  of  the  LVAD  was  unchanged
at  around  5  L/min  (for  a  speed  of  2800  rpm).  Transthoracic
echocardiography  showed  that  the  left  ventricle  was  not
dilated  but  that  the  right  ventricle  was  dilated  with  severe
impairment  of  systolic  function.
After  reduction  of  the  LVAD  ﬂow  (2600  rpm)  and  inotropic
drugs,  the  patient’s  status  improved.  Transthoracic  echocar-
diography  showed  that  the  RV  diameter  was  decreased  and
the  left  ventricular  (LV)  diameter  was  increased.
We  deduced  RV  failure  (RVF)  worsened  by  too  high  a  ﬂow
speed.
Patient  4:  Biventricular  HeartWare  VAD  —
pulmonary overﬂow  of  the  RVAD  and  tamponade
A  41-year-old  woman  with  dilated  cardiomyopathy  of
unknown  aetiology  presented  in  October  2010  with  refrac-
tory  cardiogenic  shock  (INTERMACS  1).  HeartWare  BiVAD
implantation  was  performed  because  of  biventricular
dysfunction  and  the  primary  postoperative  course  was
uneventful.
At  day  21,  the  patient  had  pulmonary  insufﬁciency  with-
out  sign  of  infection.  RVAD  ﬂow  was  5.2  L/min  (2400  rpm)
and  LVAD  ﬂow  was  6.6  L/min  (2600  rpm).  The  measurement
of  CVP  showed  a  pressure  of  16  mmHg.  X-ray  examination
showed  alveolar-interstitial  pulmonary  oedema.  Echocar-
diography  eliminated  tamponade.
We  concluded  that  there  was  pulmonary  overﬂow  of  the
RVAD  and  the  course  was  favourable  with  an  increase  in  left
pump  ﬂow  (2900  rpm)  and  2  days  of  intravenous  diuretics.
After  4  weeks  (day  29),  the  patient  developed  dysp-
noea  with  orthopnoea  a  few  hours  after  withdrawal  of
the  epicardial  electrode.  The  ﬂows  decreased:  RVAD  ﬂow
was  3.3  L/min  (2400  rpm)  and  LVAD  ﬂow  was  3.9  L/min
(2900  rpm).  CVP  increased  to  19  mmHg.  X-ray  investigation
showed  cardiomegaly  (Fig.  1).  Tamponade  was  suspected
and  conﬁrmed  by  echocardiography.  The  patient  under-
went  emergency  surgery,  the  haematoma  was  evacuated
and  haemodynamic  status  stabilized  immediately  (RVAD  ﬂow
4.6  L/min  and  LVAD  ﬂow  5.8  L/min).  The  patient  was  reha-
bilitated.
Patient  5:  CardioWest  total  artiﬁcial  heart  —
multifactorial HF
A  56-old-man  presented  with  a  15-year  history  of  valvu-
lar  cardiomyopathy  with  aortic  stenosis  and  severe  LV
dysfunction.  He  had  chronic  renal  insufﬁciency  (creati-
nine  2.1  mg/dL).  In  September  2010,  clinical  deterioration
led  to  implantation  of  biventricular  support;  a  CardioW-
est  TAH  was  selected  due  to  severe  calciﬁcations  of  the
ascending  aorta.  Immediate  follow-up  was  complicated  by
tamponade,  which  required  new  surgical  intervention,  and
by  cerebral  bleeding.  For  cerebral  protection,  the  patient
received  hypertonic  serum  (mannitol)  for  3  days  and  diuret-
ics  were  stopped.  One  week  after  the  neurological  event,
the  patient  developed  clinical  signs  of  HF  with  dyspnoea
and  peripheral  oedema.  The  TAH  ﬂow  was  unchanged
at  8.6  L/min  (with  a  vacuum  of  9  mmHg  and  a  ﬁxed
beat  of  130/min).  CVP  was  24  mmHg.  X-ray  investigation
showed  alveolar-interstitial  pulmonary  oedema.  Thoracic
computed  tomography  eliminated  tamponade.  After  3  days
L
h
t
aigure 1. X-ray examination shows cardiomegaly with a Heart-
are BiVAD and alveolar-interstitial pulmonary oedema.
f  treatment  with  intravenous  diuretics,  the  signs  disap-
eared.  We  deduced  volume  overload  worsened  by  renal
ailure.
One  month  later,  the  patient  again  presented  clinical
igns  of  HF  with  dyspnoea  and  peripheral  oedema.  The
AH  ﬂow  was  8.2  L/min  (with  a  vacuum  of  9  mmHg  and  a
xed  beat  of  130/min).  CVP  was  19  mmHg.  X-ray  investiga-
ion  showed  alveolar-interstitial  pulmonary  oedema.  Renal
unction  was  impaired.  Blood  pressure  was  not  completely
ontrolled  (systolic  arterial  pressure  around  130  mmHg).
ymptoms  improved  after  diuretic  therapy  and  antihyper-
ensive  agents.
The  clinical  presentation  could  be  explained  by  impaired
enal  function  and  uncontrolled  blood  pressure.  The  patient
as  ﬁnally  discharged  with  TAH  support.
F after the ﬁrst year post-VAD insertion
atient  6:  HeartMate  II  LVAD  —  device  malfunction
 72-year-old  man  received  a  HeartMate  II  LVAD  as  des-
ination  therapy  in  2009  for  ischaemic  cardiomyopathy.
ollow-up  was  uneventful  and  the  patient  lived  with  his
ife  at  home.  The  patient  was  readmitted  on  December
010  due  to  stage  IV  dyspnoea,  oedema  and  ascites.  Pump
ow  was  low  (3.6  L/min  for  2900  rpm)  with  a  decreased
ulsatility  index  (13)  and  normal  power  (3.5  watts).  PAC
howed  a  CI  of  1.5  L/min/m2,  a  CVP  of  27  mmHg  and  a  PCWP
f  31  mmHg.  X-ray  examination  showed  cardiomegaly  with
lveolar-interstitial  oedema.  The  international  normalized
atio  was  6.6.  Renal  and  hepatic  functions  were  impaired.
actate  dehydrogenase  was  high  (793  IU/L)  whereas  free
aemoglobin  was  normal.  Echocardiography  showed  dilata-
ion  and  severe  dysfunction  of  both  ventricles  and  an  opened
ortic  valve.  A  mechanical  dysfunction  of  the  pump  was
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oigure 2. In a post-mortem analysis of the inﬂow cannula, we can
ee a thrombus.
uspected  but  it  was  decided  not  to  operate  and  to  attempt
edical  treatment  (inotropic  drugs,  diuretics  and  haemodi-
ﬁltration).  The  patient  died.
Post-mortem  analysis  of  the  pump  showed  a  massive
hrombosis  of  the  apical  cannula  (Fig.  2).
iscussion
he  six  case  reports  illustrate  the  different  possible  aeti-
logies  of  a  clinical  presentation  of  HF  in  patients  with  a
AD.  In  the  postoperative  course  of  VAD  implantation,  a  clin-
cal  presentation  of  HF  is  not  rare.  The  mechanisms  may  be
omplex,  with  multiple  contributing  factors  [12].
ifferent mechanisms of oedema syndrome
ardiogenic  shock  is  accompanied  by  the  production
f  numerous  inﬂammatory  cytokines  (interleukin-1,
nterleukin-6,  interleukin-8,  tumour  necrosis  factor-, C-
eactive  protein,  soluble  adhesion  molecules,  complement
ystem)  due  to  expression  of  inducible  nitric  oxide  synthase
13,14].  This  activation  of  the  inﬂammatory  response  causes
n  alteration  of  vascular  permeability  and  participates  in
he  formation  of  oedema.  These  signs  are  worsened  by
asoplegic  syndrome,  which  occurs  after  cardiac  surgery
ith  an  incidence  ranging  between  5%  and  25%  [15,16].
asoplegic  syndrome  is  due  to  a  systemic  inﬂammatory
esponse  and  is  characterized,  among  other  things,  by  low
ystemic  vascular  resistance  [17].
Moreover,  in  the  early  postoperative  period,  LVAD  results
n  decreased  RV  function.  RV  preload  is  reduced  because  of
he  improvement  in  cardiac  output.  The  afterload  increases
ue  to  the  septal  shift  (causing  increased  RV  wall  stress),
econdary  to  LVAD  implantation,  pulmonary  vasoreactiv-
ty,  blood  transfusion  and  inﬂammation  induced  by  surgery
18—20].  The  decreased  RV  function  contributes  to  the
ppearance  of  HF  signs.Preoperatively,  patient  status  was  often  poor,  with  car-
iogenic  shock  accompanied  by  multiple  organ  failure,
articularly  renal  and  hepatic  failure  [1,21]. After  VAD
mplantation,  the  impaired  organs  need  time  to  recover.  In
V
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aN.  Aissaoui  et  al.
 study  conducted  by  Friedel  et  al.,  in  61  patients  assisted
y  a  BiVAD  (n  =  54),  an  LVAD  (n  =  5)  and  a  TAH  (n  =  2)  in  order
o  bridge  to  transplantation,  functional  recovery  of  hepatic
nd  renal  failure  was  observed  in  90%  and  95%  of  cases  [22].
he  mean  duration  of  organ  recovery  after  mechanical  cir-
ulatory  support  was  between  10  and  15  days.  Nevertheless,
n  this  study,  21  patients  died  because  of  multiorgan  failure
r  septic  complications.
Impaired  renal  function  helps  to  maintain  and  worsen
he  signs  of  HF  after  VAD  implantation.  Heart  and  kidney
erformance  are  closely  inter-related  physiologically  and
athophysiologically,  both  in  health  and  in  disease  [23—25].
efore  VAD  implantation,  for  the  patient  with  HF  and  volume
verload,  the  combination  of  high  pulmonary  artery  or  cen-
ral  venous  pressure  with  low  systemic  pressure  alters  the
enal  perfusion  pressure.  Neurohormonal  activation  plays
 major  role  in  these  phenomena.  Mediated  by  activation
f  arterial  baroreceptors  and  intrarenal  sensors,  it  results
n  abnormal  activation  of  the  renin-angiotensin-aldosterone
ystem,  activation  of  the  sympathetic  nervous  system  and
ctivation  of  the  arginine-vasopressin  system.  All  of  these
henomena  are  responsible  for  increased  preload  and  after-
oad  (caused  by  vasoconstriction  and  sodium  retention)  and
ctivation  of  nitric  oxide  synthase,  leading  to  initiation  of
n  inﬂammatory  response  and  secretion  of  proinﬂammatory
ytokines  with  negative  inotropic  effects.  This  vicious  cycle
amages  the  heart  and  kidneys.  After  VAD  implantation,
enal  function  remains  impaired  for  a  few  weeks  and  leads  to
ncreases  in  preload  and  afterload.  Impaired  renal  function
s  also  responsible  for  a  maladaptive  response  to  overload
olume  [26].
Congestive  liver  dysfunction  induces  elevation  of  hepatic
nzymes  and  hypoalbuminaemia  [27]. In  fact,  hypoalbu-
inaemia  is  multifactorial  and  is  caused  by  malnutri-
ion,  inﬂammation,  cachexia,  haemodilution,  protein-losing
nteropathy,  increased  transcapillary  escape  rate  and
ephrotic  syndrome.  According  to  Starling’s  law,  hypoalbu-
inaemia  leads  to  a  low  plasma  oncotic  pressure,  which
nduces  a  ﬂuid  shift  from  the  intravascular  to  the  intersti-
ial  space;  it  facilitates  the  onset  of  cardiogenic  pulmonary
edema  [28—30].
Finally,  oedema  can  be  caused  by  high  hydrostatic  pres-
ure  resulting  from  ﬂuid  overload  during  the  perioperative
eriod,  which  is  usually  mediated  by  neurohormonal  renal
alt  and  water  retention.  Systemic  venous  pressure  increases
nd  contributes  to  the  cycle  of  oedema  formation  [12].
Nevertheless,  the  symptoms  of  HF  can  persist  or  appear
ater,  whereas  the  patients  recover  normal  hepatic  and  renal
unction.  Other  causes  more  speciﬁc  to  VAD  patients  can
xplain  these  presentations.
he load sensitivity of VAD
ADs  are  preload  dependent  and  afterload  sensitive
31—35].
The  LVAD  can  be  compared  to  a  ‘normal  heart’  in  terms
f  preload  dependence.  For  the  same  pump  speed,  when  a
AD  patient  receives  ﬂuid,  the  ﬂow/output  of  the  LVAD  is
ncreased.  From  a  certain  threshold,  when  the  right  ventri-
le  has  failed,  the  LVAD  cannot  be  ﬁlled;  the  ﬂow  decreases
nd  clinical  symptoms  of  HF  appear  [32,35].
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DHeart  failure  while  on  VAD  support  
With  a  BiVAD,  RVF  should  not  develop  because  the  right
ventricle  is  assisted.  But  when  the  ﬂow  of  the  RVAD  is  too
high,  the  blood  cannot  be  evacuated  by  the  LVAD  and  pul-
monary  oedema  can  occur  [34]. This  situation  is  reversible
after  an  increase  of  LVAD  ﬂow.  Nonaka  et  al.  recommend
maintaining  certain  conditions  during  rotary  pump  BiVAD
implantation  to  avoid  this  pulmonary  congestion:  a  ratio
between  right  and  left  VAD  ﬂow  of  <  1  and/or  an  aver-
age  pulmonary  artery  ﬂow  rate  <  160  mL/kg/min  and  systolic
pulmonary  artery  pressure  <  50  mmHg  [33].
The  use  of  continuous-ﬂow  HeartWare  pumps  as
implantable  BiVADs  is  more  recent.  In  a  study  of  eight
patients,  Hetzer  et  al.  described  overﬂow  pulmonary
oedema  in  one  patient  who  died  as  a  result  [36]. LVAD  and
RVAD  at  the  same  speed  can  have  different  ﬂows  due  to  the
difference  in  pulmonary  vascular  resistance  and  systemic
vascular  resistance.  Thus,  the  right  pump  in  a  normal  pul-
monary  resistance  circuit  would  pump  more  volume  than  the
left  and  induce  pulmonary  oedema.
All  VADs,  especially  those  with  centrifugal  and  axial
ﬂow  pumps,  are  sensitive  to  afterload  [36]. Patients
with  implanted  VADs  recover  sufﬁcient  output  and  can
develop  arterial  hypertension  [37]. From  a  certain  level
of  blood  pressure,  the  ﬂow  will  decrease  and  pulmonary
congestion  can  appear  [31,35].  A  mean  arterial  blood  pres-
sure  >  75  mmHg  leads  to  the  opening  of  the  aortic  valve  and
inadequate  functioning  of  the  LVAD  [38].
Speciﬁcity of the CardioWest TAH: heart
insufﬁciency with a higher VAD ﬂow
The  CardioWest  TAH  is  a  biventricular  orthotopic  pneumatic
pulsatile  blood  pump,  which  replaces  the  failing  atria  and
ventricles  of  the  heart  as  well  as  the  proximal  portion  of
each  great  vessel;  it  is  driven  by  an  external  console.  For
each  ventricle,  the  length  of  the  blood-ﬂow  path  is  shorter
and  the  inﬂow  and  outﬂow  valves  are  larger  than  in  any
other  bridge-to-transplant  device,  resulting  in  greater  blood
ﬂow  at  smaller  preload.  The  console  settings  include  left
ventricular  and  RV  pressures  of  190  and  70  mmHg,  respec-
tively.  The  settings  of  the  TAH  are  relatively  ﬁxed:  the  beat
ranges  between  120  and  130/min;  stroke  volume  is  constant
at  70  mL;  the  vacuum  averages  9  mmHg;  and  the  percentage
systole  averages  53%.  The  CardioWest  TAH  therefore  has  an
output  range  of  7—9  L/min  [39,40].
Orthotopic  positioning  eliminates  concerns  about  prob-
lems  resulting  from  the  native  heart,  such  as  right  HF,
arrhythmias,  problems  with  native  and  prosthetic  heart
valves,  clots  within  the  native  ventricles,  ventricular  septal
defects,  rejection  and  infarction  and  stone  heart.  Never-
theless,  signs  of  HF  can  happen.  In  the  immediate  follow-up
after  implantation,  complications  such  as  atrial  compression
and  tamponade  have  to  be  eliminated.  Later,  the  aetiology
is  multifactorial.  Impaired  renal  function  with  inadequate
diuresis  can  contribute  to  clinical  signs  of  ﬂuid  retention.
Like  other  VADs,  the  TAH  is  preload  and  afterload  depend-
ent.  Due  to  its  high  output,  the  TAH  can  induce  arterial
hypertension,  which  may  increase  afterload  and  signs  of  HF.
In  summary,  there  are  numerous  mechanisms  responsible  for
clinical  signs  of  HF  in  TAH  patients  with  high  ﬂow.
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Oedema  can  be  controlled  with  diuretic  therapy,  which
as  to  be  chronic.
eart insufﬁciency and low VAD ﬂow
n  a  clinical  presentation  of  HF  with  decreased  VAD  ﬂow,
hree  diagnoses  should  be  investigated:  tamponade,  RVF  and
AD  malfunction.
amponade
 clinical  presentation  of  HF  makes  it  necessary  to  exclude
amponade  by  echocardiography  or  thoracic  computed
omography,  especially  if  CVP  is  elevated  without  oedema
yndrome.  Tamponade  is  not  rare  after  VAD  implantation  (up
o  30%)  and  often  occurs  in  the  ﬁrst  days  after  implantation
41,42];  it  increases  the  mortality  of  VAD  patients  [42].
ight  ventricular  failure
VF  is  a  severe  problem  in  LVAD  patients;  its  incidence  varies
rom  7%  to  50%  and  it  is  responsible  for  increased  perioper-
tive  and  1-year  mortality  (19%  to  43%)  [19,41,43—45].
The  pathophysiology  of  RVF  is  complex.  In  the  long  term,
VAD  improves  RV  function  by  LV  unloading  and  decreasing  LV
lling  pressure  and  pulmonary  venous  return.  Nevertheless,
n  the  early  postoperative  period,  many  mechanisms  may
ontribute  to  RVF,  as  described  at  the  beginning  of  discussion
18—20].  RVF  leads  to  liver  and  renal  failure,  oedema  and
scites  [41,44]; it  induces  underﬁlling  of  the  left  ventricle
nd  the  pump  with  potential  arrhythmia  and  cardiac  failure
19,43—45].
Prediction  of  RVF  after  LVAD  placement  would  lead  to
ore  precise  patient  selection  and  optimal  device  selec-
ion.  Many  studies  have  tried  to  identify  factors  that  predict
VF  after  LVAD  implantation  [19,43—45].  Clinical  and  biolog-
cal  factors  such  as  sex  (female),  dilated  cardiomyopathy,
revious  cardiac  surgery  and  biological  factors  reﬂecting
epatic  and  renal  failure  were  associated  with  postop-
rative  RVF  in  LVAD  patients.  Some  haemodynamic  and
chocardiographic  indices  were  assessed  but  the  results
ere  discordant  [19]. Because  of  the  multiplicity  of  factors
ontributing  to  RVF  after  LVAD  implantation,  some  scores
ere  developed  [44,45].  However  the  prediction  of  postop-
rative  RV  dysfunction  remains  difﬁcult.
Despite  its  effectiveness  in  the  treatment  of  severe  RVF,
he  use  of  biventricular  mechanical  support  for  end-stage
ongestive  HF  remains  controversial  because  patients  who
equire  prolonged  support  with  a  BiVAD  have  a  lower  sur-
ival  rate  than  recipients  of  a  LVAD.  In  addition,  BiVAD
ecipients  have  higher  rates  of  major  adverse  events,  such
s  thromboembolisms,  device  infections  and  mechanical
omplications  [19,43]. RVF  after  LVAD  can  also  be  managed
edically  with  pulmonary  vasodilators,  including  nitroprus-
ide,  nitric  oxide  and  iloprost,  and  inotropes  or  with  a
emporary  RVAD  [46].
evice  malfunction
evice  malfunction  is  principally  due  to  mechanical  fail-
re  or  thrombosis  [42,44,47,48]; its  incidence  increases  with
ime,  with  a  cumulative  probability  of  6%  at  6  months  and
4%  at  2  years  [47]. Device  malfunction  should  be  consid-
red  when  VAD  ﬂow  is  low  with  HF  presentation.  Sometimes,
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[0  
he  clinical  presentation  is  associated  with  haemolysis  and
n  increase  in  the  power  of  the  device.  Device  malfunc-
ion  leads  to  death  in  <  5%  of  cases  but  otherwise  does
equire  replacement  of  the  mechanical  circulatory  support
33,34,36].
anagement
efore  the  VAD  implantation
ptimization  of  patient  status  before  implantation  should
orrect  additional  factors  responsible  for  ﬂuid  retention.
his  involves  optimization  of  liver  and  renal  function,
ssessment  of  nutritional  status  and  improvement,  when
ecessary,  of  nutritional  and  metabolic  status.  Optimization
f  status  before  VAD  surgery,  however,  is  often  not  possible
n  these  patients  because  implantation  is  often  an  emer-
ency  procedure  (INTERMACS  1,  2  or  3).  Some  studies  suggest
hat  the  risk  of  RVF  can  be  decreased  by  preoperative  opti-
ization  of  nutrition,  haemodynamics  and  organ  function,
nd  by  minimization  of  RV  preload  with  inotropic  drugs  and
n  intra-aortic  balloon  pump.  Limiting  bleeding  and  trans-
usion,  avoiding  surgical  RV  injury  and  distension,  tricuspid
nnuloplasty,  early  cessation  of  positive  pressure  ventilation
nd  RV  afterload  reduction  could  also  improve  RVF  after  LVAD
28,47].
fter  the  VAD  implantation
fter  the  diagnosis  of  HF  symptoms  in  VAD  patients,  it
s  important  to  discount  complications  that  could  require
mergency  surgery,  such  as  tamponade  or  device  malfunc-
ion.
Concerning  RVF,  when  echocardiography  has  shown  that
he  LV  diameter  is  small,  the  aortic  valve  is  closed  and  the
ight  ventricle  is  dilated,  a  reduction  in  LVAD  speed  can
mprove  RV  function  by  increasing  preload  and  decreasing
eptal  shift.
Overload  volume  should  be  avoided  or  corrected  by
iuretic  therapy.  Control  of  the  afterload  includes  control
f  blood  pressure.  Mean  arterial  blood  pressure  in  the  range
f  65  to  75  mmHg  is  recommended  throughout  LVAD  support
o  avoid  opening  of  the  aortic  valve  and  inadequate  func-
ioning  of  the  LVAD  [38]. Most  patients  show  a  good  and  fast
esponse  to  intravenous  diuretic  therapy.
Finally,  VAD  patients  should  have  strict  blood  pressure
ontrol  and  small  doses  of  diuretics  to  avoid  volume  over-
oad.
onclusion
ur  six  case  reports  illustrate  the  different  causes  of  signs
f  HF  in  VAD  patients.  In  the  postoperative  course  after  VAD
mplantation,  a  clinical  presentation  of  HF  is  not  rare.  VAD
atients  need  time  for  recovery  after  implantation  because
hey  often  have  multiple  organ  failure  and  inﬂammatory
eaction  due  to  cardiogenic  shock  and  cardiac  surgery.  Later,
he  appearance  of  HF  should  prompt  examination  for  RVF  or
or  complications  associated  with  the  use  of  a  VAD.  Registries
uch  as  European  Registry  for  Patients  with  Mechanically
ssisted  Circulatory  Support  (EUROMACS)  and  INTERMACS
[
[N.  Aissaoui  et  al.
ould  increase  understanding  of  this  important  issue  and
ssess  the  repercussions.
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